Skip to main content

Immunotherapy

When Does Immunotherapy Work Best in Lung Cancer?

By Wayne Kuznar

Immunotherapy, Lung Cancer

September 2017, Vol 7, No 9

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

By Eileen Koutnik-Fotopoulos

ASCO 2017 Highlights, Immunotherapy

July 2017, Vol 7, No 7

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read More ›

NCCN Updated Lung Cancer Guidelines Focus on Immunotherapy

July 2017, Vol 7, No 7

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

July 2017, Vol 7, No 7

Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

By Phoebe Starr

June 2017, Vol 7, No 6

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

May 2017, Vol 7, No 5

Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab

May 2017, Vol 7, No 5

Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer

March 2017, Vol 7, No 3

Urelumab Safe and Active as Monotherapy and in Combination with Nivolumab in Several Types of Cancer

By Walter Alexander

January 2017, Vol 7, No 1

Virtual Tumor Boards Expand Access to Clinical Trials and Immunotherapy in the Community Center Setting

By Meg Barbor, MPH

November 2016, Vol 6, No 11

Page 5 of 6

2
3
4
5
6